Dermata Therapeutics Announces Private Placement Financing

What Happened
Dermata Therapeutics, Inc. announced on August 16, 2026 that it entered a securities purchase agreement for a private placement that will raise approximately $3.2 million net. The transaction includes (i) 933,064 shares of common stock, (ii) pre‑funded warrants to buy up to 1,360,544 shares (exercise price $0.001), and (iii) Series E and Series F warrants to purchase up to 2,293,608 shares each (warrant exercise price $1.46). Company insiders — including the CEO and CFO — participated, purchasing an aggregate of 4,897,956 shares and warrants (including all 1,360,544 pre‑funded warrants) for about $2.4 million.

Key Details

• Total net proceeds to Dermata are estimated at approximately $3.2 million after fees and expenses.
• Purchase prices: $1.46 per share with accompanying warrants; $1.459 per pre‑funded warrant with accompanying warrants; insiders paid $1.47/$1.469 for their securities.
• Warrants: Pre‑funded warrants exercisable immediately ($0.001 exercise price); other warrants exercisable only after shareholder approval of the shares issued on exercise; Series E expire 5 years from that approval, Series F expire 24 months.
• Additional placement terms: registration rights require filing a resale registration statement within 60 days and use best efforts to have it declared effective within 90 days (120 days if SEC full review). The company issued a broker warrant for 35,958 shares and paid a $52,500 fee to the bank.

Why It Matters
This financing provides Dermata with near‑term cash to fund planned activities (OTC acne kit pre‑launch/launch, consumer research, licensing, potential acquisitions and working capital) while diluting current shareholders depending on future warrant exercises. Insider participation signals management support for the financing but also means related‑party purchases occurred. Investors should note the registration timetable (resale of these securities) and that many warrants cannot be exercised until shareholder approval is obtained.